SIRT1

Across TCGA pan-cancer cohorts, SIRT1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SIRT1 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SIRT1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SIRT1 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LSCC, and CCRCC are the cancer types where SIRT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	IV	0.951	0.381	.006	12	view →
LSCC	OS	Median	All	0.806	0.935	.017	8	view →
CCRCC	DFS	Median	All	0.609	0.926	.034	1	view →
LUAD	DFS	Median	II,III,IV	0.812	0.894	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SIRT1–PDAC (OS)

Open the PDAC breakdown →